GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Echo Therapeutics (ECTE) [hlAlert]

Rating:
Buy ECTE
down 91.85 %

Echo Therapeutics (ECTE) rated Buy with price target $2.35 by Feltl & Co.

Posted on: Monday,  May 14, 2012  8:25 AM ET by Feltl & Co.

Feltl & Co. rated Buy Echo Therapeutics (NASDAQ: ECTE) on 05/14/2012, when the stock price was $18.30. Since
then, Echo Therapeutics has lost 91.86% as of 01/26/2016's recent price of $1.49.
If you would have followed this Feltl & Co.'s recommendation on ECTE, you would have lost 91.85% of your investment in 1352 days.

Echo Therapeutics, Inc. (Echo) is a medical device and specialty pharmaceutical company. The Company is developing a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for use in clinical settings and for people with diabetes together with a range of transdermal reformulations of specialty pharmaceutical products approved by the United States Food and Drug Administration (FDA). The Symphony tCGM System is a non-invasive (needle-free), wireless tCGM system designed to provide blood glucose data. Symphony incorporates the feedback mechanism for optimal skin permeation control and the transdermal sensor to detect glucose trends, for controlling complications associated with blood glucose levels that stray outside of a target range. Symphony incorporates the skin permeation, transdermal sensor, wireless transmission and data display technologies. The specialty pharmaceuticals pipeline is based on the AzoneTS transdermal drug reformulation technology.

Feltl and Company's Research Department is focused on micro to small market capitalization companies that are not widely covered by other research firms. Our research universe is focused and organized around the sectors of Technology, HealthCare, and Leisure/Consumer. Feltl and Company holds its research department to very high standards, and strives to provide value- added investment ideas through sound fundamental analysis. Feltl and Company's Research Department includes six senior analysts and one associate analyst with many years of investment analysis experience. Although we are focused on, and committed to, companies in the Upper Midwest, our reach extends from coast to coast. About half of the companies we cover are headquartered outside our "backyard." Our analysts have significant industry experience and strive to know their companies inside and out. Through stringent analysis, they provide value by creating a disciplined application of company valuation, allowing our clients to make sound investment decisions.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/11/2013 3:25 PM Buy
None
3.35 8.00
as of 12/31/2012
1 Week up  5.05 %
1 Month down  -13.33 %
3 Months down  -33.75 %
1 YTD down  -43.16 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/26/2013 3:25 PM Buy
None
3.91 9.35
5/14/2012 8:25 AM Buy
None
18.30 23.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy